TECHWIRE 30
(CIX: WRAL30)  996.45  down arrow-8.5  (-0.85 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Apple)  524.75  down arrow-6.95  (-1.31 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: QUINTILES)  49.47  down arrow-0.48  (-0.96 %)  Updated: 06:40 PM EDT, Apr 23 2014
(OP: BASF SE)  112.59  down arrow-0.25  (-0.22 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: BioCryst)  8.55  down arrow-0.65  (-7.07 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: BioDelivery)  8.66  up arrow+0.19  (2.24 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: CEMP)  9.92  down arrow-0.49  (-4.71 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Cisco Systems)  23.50  down arrow-0.02  (-0.09 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Cornerstone)  9.49    (0 %)  Updated: 08:10 PM EST, Feb 03 2014
(NQ: Cree)  51.04  down arrow-7.01  (-12.08 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: DARA)  1.88  up arrow+0.05  (2.73 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: EMC CORPORATION)  25.91  down arrow-0.85  (-3.18 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: Extreme Networks)  5.70  down arrow-0.09  (-1.55 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Facebook)  61.36  down arrow-1.67  (-2.65 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: GLAXOSMITHKLINE)  55.14  down arrow-0.16  (-0.29 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: GOOG)  526.94  down arrow-7.87  (-1.47 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: IBM)  191.73  down arrow-0.42  (-0.22 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NY: LH)  99.85  down arrow-0.53  (-0.53 %)  Updated: 06:40 PM EDT, Apr 23 2014
(OP: Lenovo Group)  22.76  down arrow-0.43  (-1.85 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: MRK)  57.50  down arrow-0.27  (-0.47 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: Microsoft Corp)  39.69  down arrow-0.3  (-0.75 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: NetApp)  35.87  down arrow-0.18  (-0.49 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: NOVARTIS AG)  86.17  down arrow-0.39  (-0.45 %)  Updated: 06:40 PM EDT, Apr 23 2014
(OP: Novozymes A/S)  46.99  up arrow+0.98  (2.13 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: PFIZER)  30.92  down arrow-0.08  (-0.26 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: Pozen)  9.22  down arrow-0.03  (-0.32 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NY: RED HAT)  50.05  down arrow-0.85  (-1.67 %)  Updated: 06:40 PM EDT, Apr 23 2014
(NQ: BBRY)  7.36  up arrow+0.07  (0.96 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: Salix)  109.95  up arrow+0.88  (0.81 %)  Updated: 08:10 PM EDT, Apr 23 2014
(NQ: SQI)  26.18  down arrow-0.8  (-2.97 %)  Updated: 08:10 PM EDT, Apr 23 2014

Posts tagged “GSK”

12:28 p.m. today

Government contracts likely mean immunity for big Novartis vaccine plant

Plans for pharmaceutical giants Novartis, GlaxoSmithKline and Eli Lilly to swap business lines may have shaken up the stock market Tuesday, but work at a Novartis flu vaccine plant in Holly Springs hummed along, and local officials said they expect it to remain that way.

Novartis plant in Holly Springs Novartis plant in Holly Springs

Updated 11:22 a.m. yesterday

Glaxo CEO: Major deals to 'improve long-term earnings'

GSK's top executive Andrew Witty says the multiple deals announced early Tuesday with Novartis promise to deliver "broadly sustainable sourced sales growth and improve long-term earnings."

Andrew Witty   Andrew Witty

Updated 11:21 a.m. yesterday

Novartis swaps businesses with GSK, plans to sell Holly Springs plant

Novartis Two drug giants with major operations in the Triangle, Novartis and GlaxoSmithKline, are swapping businesses in two major deals. Meanwhile, Novartis plans to sell its huge Holly Springs plant in a separate deal and also strikes an agreement to sell its animal health business to Eli Lilly. No layoffs are planned, Novartis says.

Updated 11:15 a.m. yesterday

Premium Lock Novartis-GSK deals slide show: How they change Novartis

Drug giants Novartis and GlaxoSmithKline each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the Novartis presentation.

Novartis gains GSK's oncology portfolio Novartis gains GSK's oncology portfolio

Updated 11:13 a.m. yesterday

Premium Lock GSK-Novartis deals slide show: How they change GSK

Drug giants GlaxoSmithKline and Novartis each offered investors online presentations that spell out graphically how the deals announced Tuesday will affect each company. Here's a look at three key slides from the GSK presentation.

GSK's proposed new vaccine portfolio GSK's proposed new vaccine portfolio

April 17

GSK acknowledges more employee bribery allegations

GSK The drug giant issues a statement reiterating it has "zero tolerance for unethical or illegal behavior" and says 48 employees were fired in 2013. The statement comes after reports that bribery probes are underway in two more countries.

April 16

FDA approves once-a-week GSK injectable diabetes drug

Diabetes GlaxoSmithKline has won FDA approval for its new diabetes drug which is injectable and will be used once a week. It will compete with Novo Nordisk's Victoza, which is injected daily.

Updated April 15

Bribery investigations continue to surface for Glaxo

The BBC is reporting that pharmaceutical company GlaxoSmithKline is accused of bribing doctors to prescribe medicines in Poland, making this the third country to have an investigation currently ongoing.

GSK's HQ in London     GSK's HQ in London

April 8

GSK launches probe into Iraq bribery claims

GSK's HQ in London     Drug giant GlaxoSmithKline said Monday it has launched an investigation into allegations it bribed doctors in Iraq, as the pharmaceuticals giant remains embroiled in a major corruption scandal in China.

Updated March 5

Premium Lock GSK, J&J preparing to test once-a-month AIDS medicines

HIV research GlaxoSmithKline and Johnson & Johnson are preparing to test the first monthly injections of experimental AIDS drugs in a study that may transform the treatment of the deadly disease.

Updated February 27

Premium Lock GSK cuts CEO's bonus some 12 percent due to China scandal

Andrew Witty   "Both Sir Andrew and the board are mindful of the impact this issue has had on the reputation of the company," GSK's chairman says. "As a result, the bonuses awarded for 2013 were lower than they otherwise might have been."

February 26

Premium Lock Novartis joins GSK, Sanofi in opening some drug trial data to researchers

Drug research Novartis will join companies such as GlaxoSmithKline and Sanofi in allowing researchers access to clinical trial data, as regulators demand more transparency.

February 21

Premium Lock GSK lung drug Anoro recommended for European approval

Lung disease Anoro may help GSK protect its respiratory business, which made up 42 percent of its total pharmaceutical sales last year. The company's top-selling product, Advair for smokers' cough and asthma, is facing increasing competition from a newly approved generic in Europe and cheaper options in the U.S.

February 4

Premium Lock GSK, others team with NIH in $230M effort to fight Alzheimer's, other diseases

Alzheimer's Data generated from the work will be made public for other scientists to use, a move that the U.S. National Institutes of Health called groundbreaking. The targeted diseases are some of the most prevalent conditions among Americans, costing the nation billions of dollars in treatment and lost productivity.

Updated January 31

Premium Lock 239,000 STEM jobs beckon in N.C., but report says state not delivering enough qualified students

The warning is stark: "The danger we face today is the possibility that fewer people will enter highly technical fields in the decades ahead, at a time when demand for individuals with these kinds of skills is on the rise." U.S. student achievement in STEM fields lags many industrialized countries, and North Carolina students lag many states. But pharma companies are stepping in to help bridge the gap. WRALTechWire examines the report from Battelle and its implications for North Carolina as well as the U.S.

STEM acheivement in science STEM acheivement in science

Updated January 22

Premium Lock RTI partners on epilepsy work; SAS ranked in report; lawyers use cloud tools; Kenan-Flagler dean recommended; Abbott gets new trial

Bulldog In our Bulldog Blog's latest life sciences and technology update: RTI partners on epilepsy network; SAS makes ranking; lawyers use more cloud tools; Kenan-Flagler dean recommended; AbbVie gets new drug trial.

Updated January 22

Premium Lock GSK's joint venture HIV drug wins approval in Europe

HIV research A ViiV Healthcare combination HIV drug has received regulatory approval from the European Commission, GlaxoSmithKline says. ViiV is seeking approval for the drug in the U.S. as well.

January 15

Premium Lock GSK: China sales improving after 61% drop; CDC affirms rotavirus vaccine

GSK China GlaxoSmithKline says sales in China, where the company faces a bribery probe, have improved since the third quarter when revenue plunged 61 percent from a year earlier. In other news, the CDC affirmed support for rotavirus vaccines that combat severe diarrhea in infants from GSK and Merck.

January 13

Premium Lock GSK lands 'breakthrough' FDA designation for lung cancer treatment

GSK's HQ in London     Good news, bad news for GlaxoSmithKline on Monday: A treatment for metastatic lung cancer receives "Breakthrough Therapy" designation from the FDA. However, GSK also says it has dropped development of a muscular dystrophy treatment.

Tags: GSK
January 9

Premium Lock GSK wins 'accelerated approval' for combination cancer treatment targeting melanoma

Cancer research In what GlaxoSmithKline says is a first, the drug giant has received FDA approval for a combination of its cancer drugs that target a form of melanoma linked to specific genetic mutations.

Techwire Inside Partners
The Skinny: A Blog by Rick Smith

OUR INSIDERS

Vivek Wadhwa
Commentary
Dr. Mike Walden
Tech economy
Frank Vinluan
Life science
Scroll